Clofarabine in the treatment of acute myeloid leukaemia and acute lymphoblastic leukaemia: A review

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 15, 2005, Pages 2711-2718

  Kline, Justin P ^a   Larson, Richard A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Clofarabine

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE DEAMINASE; ANTHRACYCLINE; APOPTOSIS INDUCING FACTOR; CLADRIBINE; CLOFARABINE; CYTARABINE; CYTOCHROME P450; DEOXYCYTIDINE KINASE; DNA DIRECTED DNA POLYMERASE ALPHA; FLUDARABINE PHOSPHATE; IDARUBICIN; PENTOSTATIN; RIBONUCLEOTIDE REDUCTASE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHILDHOOD LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOTOXICITY; DIARRHEA; DNA REPLICATION; DNA SEQUENCE; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG ERUPTION; DRUG FATALITY; DRUG INFUSION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; ERYTHEMA; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HEADACHE; HIGH RISK PATIENT; HUMAN; HYPERBILIRUBINEMIA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER TOXICITY; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MITOCHONDRIAL DNA DISORDER; MONOTHERAPY; MYALGIA; NEUROTOXICITY; NONHUMAN; PROGNOSIS; REVIEW; RISK ASSESSMENT; STOMATITIS; SURVIVAL TIME; TREATMENT OUTCOME; URINARY EXCRETION;

ADENINE NUCLEOTIDES; ARABINONUCLEOSIDES; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE;

EID: 29244436105     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.15.2711     Document Type: Review

References (31)

1. PARKER WB, SHADDIX SC, CHANG EL et al.: Effects of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res. (1991) 51:2386-2394.
2. CARSON DA, WASSON DB, ESPARZA LM et al.: Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine. Proc. Natl. Acad. Sci. USA (1992) 89:2970-2974.
3. XIE KC, PLUNKETT W: Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2- deoxy-2-fluoro-β-D-arabinofuranosyl) adenine. Cancer Res. (1996) 56:3030-3037.
4. PARKER WB, SHADDIX SC, ROSE LM et al.: Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2- fluoro-β-D-arabinofuranosyl)adenine, 2-chloro-9- (2-deoxy-2-fluoro-β-D-ribofuranosyl)adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro-β-D-ribofuranosyl)adenine in CEM cells. Mol. Pharmacol. (1999) 55:515-520.
5. KUMMAR S, NORONHA V, CHU E: Antimetabolites. In: Cancer: Principles and Practice of Oncology, 7th edn. Devita VT (Ed.), Lippincott Williams and Wilkins, Philadelphia, PA (2000):358-374.
6. CARSON DA, WASSON DB, TAETLE R et al.: Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood (1983) 62:737-743.
7. GENINI D, ADACHI S, CHAO Q et al.: Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood (2000) 96:3537-3543.
8. LOTFI K, MANSSON E, SPASOKOUKOTSKAJA T et al.: Biochemical pharmacology and resistanceto 2-chloro-2′-arabinofluoro-2′-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clin. Cancer Res. (1999) 5:2438-2444.
9. MANSSON E, FLORDAL E, LILIEMARK J et al.: Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. Biochem. Pharmacol. (2003) 65:237-247.
10. MONTGOMERY JA, SHORTNACY-FOWLER AT, CLAYTON SD et al.: Synthesis and biologic activity of 2′-fluoro-2-halo derivatives of 9-β-D-arabinofuranosyladenine. J. Med. Chem. (1992) 35:397-401.
11. MARQUEZ VE, TSENG CK, KELLEY JA et al.: 2′,3′-Dideoxy-2′-fluoro-ara-a. An acid stable purine nucleoside active against human immunodeficiency virus (HIV). Biochem. Pharmacol (1987) 36:2719-2722.
12. GANDHI V, KANTARJIAN H, FADERL S et al.: Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin. Cancer Res. (2003) 9:6335-6342.
13. KANTARJIAN HM, GANDHI V, KOZUCH P et al.: Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J. Clin. Oncol. (2003) 21:1167-1173.
14. BONATE PL, CRAIG A, GAYNON P et al.: Population pharmacokinetics of clofarabine, a second generation nucleoside analog, in pediatric patients with acute leukemia. J. Clin. Pharmacol. (2004) 44:1309-1322.
15. WARRELL RP, BERMAN E: Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J. Clin. Oncol. (1986) 4:74-79.
16. JEHA S, GANDHI V, CHAN KW et al.: Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood (2004) 103:784-789.
17. KANTARJIAN H, GANDHI V, CORTES J et al.: Phase II clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood (2003) 102:2379-2386.
18. BURNETT AK, RUSSELL N, KELL JW et al.: A Phase II evaluation of single agent clofarabine as first line treatment for older patients with AML who are not considered fit for intensive chemotherapy. Blood (2004) 104(S1) (Abstr 869).
19. CHIAO N, BUMGARDNER A, DUVIC M: Clofarabine-induced acral erythema during the treatment of patients with myelodysplasia and acute leukemia: report of two cases. Leuk. Lymphoma (2003) 44:1405-1407.
20. JEHA S, GAYNON P, STEINHERZ P et al.: A Phase II, open-label study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood (2003) 102(S1): (Abstr 3277).
21. JEHA S, STEINHERZ P, GAYNON P et al.: A Phase II, open-label study of clofarabine in pediatric patients with refractory or relapsed acute myelogenous leukemia. Blood (2003) 102(S1) (Abstr 2278).
22. JEHA S, RAZZOUK BI, RYTTING ME et al.: Phase II trials of clofarabine in relapsed or refractory pediatric leukemia. Blood (2004) 104: S1 (Abstr 684).
23. COOPER T, AYRES M, NOWAK B et al.: Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother. Pharmacol. (2004) 55: 361-368.
24. FADERL S, GANDHI V, O'BRIEN S et al.: Results of a Phase I-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood (2005) 105:940-947.
25. FADERL S, GANDHI V, VERSTOVSEK S et al.: Clofarabine plus cytarabine (ARA-C) combination is active in newly diagnosed patients ≥ age 50 with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Blood (2004) 104(S1) (Abstr 875).
26. FADERL S, FERRAJOLIL A, WIERDA W et al.: Phase I study of clofarabine plus idarubicin plus cytarabine in patients with relapsed and primary refractory acute myeloid leukemia, myelodysplastic syndrome, and myeloid blast phase of chronic myeloid leukemia. Blood (2004) 104(S1) (Abstr 1809).
27. RAVINDRANATH Y: Recent advances in pediatric acute lymphoblastic and myeloid leukemia. Curr. Opin. Oncol. (2003) 15:23-35.
28. PUI CH, EVANS WE: Acute lymphoblastic leukemia. New Engl. J. Med. (1998) 339:605-615.
29. ESTEY E: How I treat older patients with AML. Blood (2000) 96:1670-1673.
30. STERNBERG A: Clofarabine Bioenvision/ILEX. Curr. Opin. Invest. Drugs (2003) 4:1479-1487.
31. FADERL S, GANDHI V, KEATING M et al.: The role of clofarabine in hematologic and solid malignancies - development of a next-generation nucleoside analog. Cancer (2005) 103(10):1985-1995.